The BCNT treatment planning for the Brookhaven trials on human gliomas
- Brookhaven National Laboratory, Upton, NY (United States)
- Idaho National Engineering Laboratory, Idaho Falls, ID (United States)
- Beth Israel Medical Center, New York, NY (United States)
Boron neutron capture therapy (BNCT) trials for human glioma (glioblastoma multiform) were initiated September 1994 at the Brookhaven National Laboratory (BNL). Patients are given p-boronophenylalanine-fructose (BPA-F) intravenously as the boron carrier followed by exposure to the epithermal-neutron beam at the Brookhaven Medical Research Reactor (BMRR). The initial phase of the study is to determine safety and toxicity of the drug and irradiation procedure. The epithermal-neutron beam was developed in a joint effort by BNL and Idaho National Engineering Laboratory (INEL) researchers. For the human trials, treatment planning and radiation dose estimation is performed using the BNCT-Rtpe and the rtt-MC computer codes developed by the INEL BNCT program. This paper discusses our initial experience using these treatment planning codes for human subjects. The basic principles of BNCT have been previously documented.
- OSTI ID:
- 411516
- Report Number(s):
- CONF-951006-; ISSN 0003-018X; TRN: 97:000769
- Journal Information:
- Transactions of the American Nuclear Society, Vol. 73; Conference: Winter meeting of the American Nuclear Society (ANS), San Francisco, CA (United States), 29 Oct - 1 Nov 1995; Other Information: PBD: 1995
- Country of Publication:
- United States
- Language:
- English
Similar Records
An update on the clinical trial of BNCT at the BMRR
A Phase 1 trial of intravenous boronophenylalanine-fructose complex in patients with glioblastoma multiforme